# OnCo record advl0912-crizotinib (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/advl0912-crizotinib/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "advl0912-crizotinib", "NCT00939770" ;
  schema:name "COG ADVL0912: crizotinib in children with ALK-driven tumours"@en ;
  schema:alternateName "ADVL0912"@en, "Crizotinib in paediatric anaplastic large cell lymphoma"@en, "Mossé 2017"@en ;
  schema:description "A lung cancer drug that blocks ALK made relapsed ALK-positive lymphoma disappear on scans in most of the children who took it."@en ;
  schema:url <https://onco.cc/trials/advl0912-crizotinib/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00939770>, <https://doi.org/10.1200/JCO.2017.73.4830> ;
  onco:status "positive" ;
  onco:tag "lymphoma-evidence-entities" ;
  onco:phase "1/2" ;
  schema:startDate "2009-09-21" ;
  onco:cancers <https://onco.cc/cancers/alk-positive-anaplastic-large-cell-lymphoma/>, <https://onco.cc/cancers/inflammatory-myofibroblastic-tumour/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:drugs <https://onco.cc/drugs/crizotinib/> ;
  onco:companies <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:terms <https://onco.cc/terms/orr/>, <https://onco.cc/terms/complete-response/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-crizotinib-paediatric-alcl-imt-jco-2017/> .